Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIncreased urination is reported by some people taking semaglutide (Wegovy), though it is not listed as a common side effect in the licensed UK product information. The most likely reason is indirect: as your body loses weight and retains less fluid, urine output can rise, and the reduced appetite that comes with semaglutide means many people drink more water to stay comfortable. These are separate from the medicine's direct action. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults taking semaglutide 2.4mg weekly for 68 weeks. The primary outcomes were body-weight change and metabolic markers. Urinary frequency was not identified as a notable adverse event in that dataset, and the Summary of Product Characteristics on the Electronic Medicines Compendium does not list it among common, uncommon or rare effects. That absence matters. It tells us that, unlike nausea or constipation, peeing more is not something a significant proportion of trial participants reported formally. What it cannot tell us is that the experience is imagined. Plenty of people taking Wegovy do notice a change in how often they urinate, and the reasons are real, they just sit one step removed from the medicine itself.
The side-effect profile the data do support is strongly gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion. These are the effects to watch, because severe or prolonged GI symptoms can lead to dehydration, which tends to reduce urine output rather than increase it. If you find yourself going to the bathroom far less than usual alongside significant nausea and vomiting, that is a dehydration signal worth acting on quickly.
Fat tissue holds surprisingly little water. Muscle and carbohydrate stores, however, hold a good deal of it. In the early weeks of weight loss, as glycogen stores deplete and inflammation reduces, the body releases fluid. This physiological housekeeping means more visits to the bathroom, particularly in the first month or two. It is not a semaglutide effect in the direct pharmacological sense, it is a weight-loss effect, and it would happen with meaningful calorie restriction from any source.
Alongside this, many people on Wegovy naturally start drinking more water. Appetite falls, meals become smaller, and staying hydrated fills some of the gap. Higher fluid intake means higher urine output. It is straightforward arithmetic, but it can feel conspicuous if you have not made the connection. Some people also reduce processed and restaurant food, which tends to be high in sodium. Less sodium means the kidneys retain less fluid, which again shows up as more frequent urination.
If you are curious about other unexpected physical changes on semaglutide, the question of feeling cold on Wegovy follows a similarly indirect logic, a reduced metabolic rate as weight falls rather than a direct drug effect. Our practical guide to being on Wegovy pulls together the most common experiences people notice day to day.
Most of the time, noticing you are using the bathroom a little more frequently is nothing to act on urgently. But some patterns warrant a prompt conversation with a clinician rather than a quiet wait-and-see. Discuss things with your prescriber if you notice: urination that is painful, burning or accompanied by lower back or flank pain (these can indicate a urinary tract infection or kidney issue); blood in the urine; a sudden and dramatic increase in urination with excessive thirst (this picture can point to diabetes-related changes, and semaglutide does affect glucose metabolism); or urine that is very dark and scanty when you have also been vomiting or had diarrhoea. The NHS patient information for semaglutide sets out which symptoms need same-day or emergency attention clearly and is worth reading alongside your medicine's own leaflet.
One thing to keep in mind: the medicine's GI effects tend to be most pronounced after starting or after a dose increase. Keeping a glass of water somewhere you'll see it regularly (the kitchen counter, the spot next to the kettle) makes it easier to stay ahead of dehydration without having to think about it.
Wegovy and its effects are covered in detail across a number of pages on this site. The full semaglutide overview explains how the medicine works and what to expect. For a closer look at the specific question of urinary frequency, our page on Wegovy and peeing more goes deeper on the physiology. There is also a separate explainer on whether semaglutide makes you pee a lot if you want a direct comparison with other medicines in this class. If you are weighing up Wegovy against alternatives, the comparison of Wegovy and Ozempic is a useful starting point for understanding the licensing distinctions.
If you have an unusual symptom and you are not sure whether it is related to treatment, our prescribers and aftercare team are available seven days a week. Or, if you are not yet on treatment and want to understand whether Wegovy could be appropriate for you, check your eligibility with a free consultation, your answers go to a GPhC-registered prescriber, not an automated system, and you'll hear back the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.